While GlaxoSmithKline (GSK) was trying to figure what to do about its advertising on the Imus’ show, the FDA approved Altabax (retapamulin), an antibiotic for the topical treatment of impetigo, caused by strains of Staphylococcus aureus or Streptococcus pyogenes. This is a new molecular entity in the U.S. Altabax was approved for use in children over nine months.
And the quote: “The introduction of Altabax comes at a time when antibiotic resistance is at an increasingly high level,” said Stan Block, MD, President, Kentucky Pediatric and Adult Research Inc. “Altabax provides clinicians with a convenient new means to effectively fight the bacteria that cause impetigo through an effect that is different from other antibiotics. In vitro, this new topical antibiotic has shown a low potential for the development of resistance, possibly because it works in a unique manner compared to other antibiotics.” (A pretty good quote for a drug approval press release.)
And the quote: “The introduction of Altabax comes at a time when antibiotic resistance is at an increasingly high level,” said Stan Block, MD, President, Kentucky Pediatric and Adult Research Inc. “Altabax provides clinicians with a convenient new means to effectively fight the bacteria that cause impetigo through an effect that is different from other antibiotics. In vitro, this new topical antibiotic has shown a low potential for the development of resistance, possibly because it works in a unique manner compared to other antibiotics.” (A pretty good quote for a drug approval press release.)